Vaccines: Worth Paying for the Value Returned

Abstract

Get full access to this article

View all access options for this article.

References

Breiman

. Vaccines as tools for advancing more than public health: Perspectives from a former director of the National Vaccine Program Office. Clin Infect Dis 2001;32: 283–8.

Grabenstein

. Immunization from the perspective of a millennium. Hosp Pharm 2000;35: 619–30.

Cochi

O'Mara

Preblud

. Progress in Haemophilus type b polysaccharide vaccine use in the United States. Pediatrics 1988;81: 166–8.

van den Oever

de Graeve

Hepp

Stroobant

Walckiers

Van Casteren

Pharmacoeconomics of immunisation: A review. Pharmacoeconomics 1993;3: 286–308.

Miller

Hinman

. Cost-benefit and cost-effectiveness analysis of vaccine policy. In: Plotkin

Orenstein

, eds. Vaccines. 3rd ed.. Philadelphia: WB Saunders, 2000: 1074–88.

Pai

Heyneman

Erramouspe

. Conjugated heptavalent pneumococcal vaccine. Ann Pharmacother 2002;36: 1403–13.

Eskola

Kilpi

Palmu

Jokinen

Haapakoski

Herva

Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344: 403–9.

Pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep 1997;46 (RR-8):1–24.

Preventing pneumococcal disease among infants and young children. MMWR Morb Mortal Wkly Rep 2000;49(RR-9):1–38.

10.

Doubilet

Weinstein

McNeil

. Use and misuse of the term “cost-effective” in medicine. N Engl J Med 1986;314: 253–6.

11.

Conway

Leese

. Routine childhood immunization: Is it worth it? Pharmacoeconomics 1993;3: 183–91.

12.

Van Damme

Beutels

. Economic evaluation of vaccination. Pharmacoeconomics 1996;9(suppl 3):8–15.

13.

Schulman

Lynn

Glick

Eisenberg

. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 1991;114: 798–802.

14.

Tengs

Adams

Pliskin

Safran

Siegel

Weinstein

Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995;15: 369–90.

15.

Stone

Teutsch

Chapman

Bell

Neumann

. Cost-utility analyses of clinical prevention services. Am J Prev Med 2000;19: 15–23.

16.

Lieu

Ray

Black

Butler

Klein

Breiman

Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000;283: 1460–8.

17.

Black

Lieu

Ray

Capra

Shinefeld

. Assessing costs and cost-effectiveness of pneumococcal disease and vaccination within Kaiser Permanente. Vaccine 2001;19(Suppl):S83–6.

18.

Updated recommendations from the ACIP in response to delays in supply of influenza vaccine for the 2000–01 season. MMWR Morb Mortal Wkly Rep 2000;49:888–92, 916.

19.

Deferral of routine booster doses of tetanus and diphtheria toxoids for adolescents and adults. MMWR Morb Mortal Wkly Rep 2001;50:418, 427.

20.

Updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage. MMWR Morb Mortal Wkly Rep 2001;50: 1140–2.

21.

Safety of group C meningococcal vaccine. Commun Dis Rep 2000;35:311, 314.

22.

Perkins

. New opportunities for prevention of meningococcal disease. JAMA 2000;283: 2842–3.

23.

Statement on recommended use of meningococcal vaccines. Can Comm Dis Rep 2001;27(ACS-6):2–36.